Results 201 to 210 of about 81,801 (247)
Some of the next articles are maybe not open access.
Augmentation therapy in α-1 antitrypsin deficiency
Expert Opinion on Biological Therapy, 2008Alpha-1 antitrypsin deficiency is a genetic disorder that leads to early-onset emphysema. Recently, exogenous supplementation of the enzyme has become a therapeutic alternative.To review the role of so-called augmentation therapy with pooled human plasma alpha-1 antitrypsin as a specific treatment for emphysema caused by alpha-1 antitrypsin deficiency ...
James Stoller, Gustavo Heresi
exaly +3 more sources
Methylphenidate Augmentation Therapy
Journal of Clinical Psychopharmacology, 1992Eight schizophrenic inpatients participated in a 2-week double-blind crossover study to test the efficacy of methylphenidate treatment for patients on a stabilized neuroleptic dose. All were young men with a childhood history of hyperactivity. The instruments used, the Brief Psychiatric Rating Scale, Scale for Assessment of Positive Symptoms, Scale for
M D, Carpenter +2 more
openaire +2 more sources
Quantitative Assessment of Augmentation Therapy
The Journal of Dermatologic Surgery and Oncology, 1990Abstract. We report the results obtained from 18 women whose facial folds and furrows were treated with augmentation therapy. The results of treatment with microlipoinjection and injectable collagen were measured and compared at regular intervals for a period of 1 year using a method of optical profilometry.
D E, Gormley, S, Eremia
openaire +2 more sources
Augmentation Strategies in Electroconvulsive Therapy
The Journal of ECT, 2010Electroconvulsive therapy (ECT) is a highly effective treatment, but strategies to enhance therapeutic outcomes are occasionally needed. This review examines the evidence for approaches used for enhancing seizure production: hyperventilation, pretreatment with xanthines, and use of remifentanil or ketamine in ECT anesthesia.
Colleen, Loo +2 more
openaire +2 more sources
Buspirone Augmentation of Antidepressant Therapy
Journal of Clinical Psychopharmacology, 1998Thirty outpatients meeting DSM-III-R or DSM-IV criteria for major depression, single or recurrent episode, and failing to respond to an adequate trial of an antidepressant (>6 weeks at recommended dosage) received buspirone (20-30 mg/day) for 4 or 5 weeks in addition to their existing antidepressant.
E C, Dimitriou, C E, Dimitriou
openaire +2 more sources
A.M.A. Archives of Internal Medicine, 1959
William Withering, in 1785, stated, in referring to digitalis: "Let the medicine therefore be given in the dose and at the intervals mentioned above:—let it be continued until it either acts on the kidneys, the stomach, the pulse, or the bowels; let it be stopped upon the first appearance of any of these effects." 1 Since that time, however, it has ...
E H, BLACKARD, T R, HARRISON
openaire +2 more sources
William Withering, in 1785, stated, in referring to digitalis: "Let the medicine therefore be given in the dose and at the intervals mentioned above:—let it be continued until it either acts on the kidneys, the stomach, the pulse, or the bowels; let it be stopped upon the first appearance of any of these effects." 1 Since that time, however, it has ...
E H, BLACKARD, T R, HARRISON
openaire +2 more sources
Micro/Nanomaterials‐Augmented Hydrogen Therapy
Advanced Healthcare Materials, 2019AbstractHydrogen therapy is an emerging and promising therapy strategy of using molecular hydrogen as a new type of safe and effective therapeutic agent, exhibiting remarkable therapeutic effects on many oxidative stress‐/inflammation‐related diseases owing to its bio‐reductivity and homeostatic regulation ability.
Gaoxin Zhou, Ekta Goshi, Qianjun He
openaire +2 more sources
Spiritually Augmented Cognitive Behavioural Therapy
Australasian Psychiatry, 2004Objective: To describe spiritually augmented cognitive behaviour therapy (SACBT) and its applications. Methods: The background for the need to incorporate spirituality into therapy is considered, and SACBT as a therapy for sustaining mental health and functional recovery is described. Cognitive and behavioural components are considered, including the
Russell F, D'Souza, Angelo, Rodrigo
openaire +2 more sources
Augmentation of Cognitive Behavioral Therapy with Pharmacotherapy
Psychiatric Clinics of North America, 2010There has long been interest in combining pharmacotherapy with psychotherapy, including cognitive behavioral therapy (CBT). More recently, basic research on fear extinction has led to interest in augmentation of CBT with the N-methyl Daspartate (NMDA) glutamate receptor partial agonist D-cycloserine (DCS) for anxiety disorders.
K A, Ganasen, J C, Ipser, D J, Stein
openaire +2 more sources